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Abstract
Although the epidemiology of Staphylococcus aureus bloodstream infection (BSI) has been changing, international comparisons are lacking.
We sought to determine the incidence of S. aureus BSI and assess trends over time and by region. Population-based surveillance was
conducted nationally in Finland and regionally in Canberra, Australia, western Sweden, and three areas in each of Canada and Denmark
during 2000–2008. Incidence rates were age-standardized and gender-standardized to the EU 27-country 2007 population. During
83 million person-years of surveillance, 18 430 episodes of S. aureus BSI were identiﬁed. The overall annual incidence rate for S. aureus
BSI was 26.1 per 100 000 population, and those for methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA)
were 24.2 and 1.9 per 100 000, respectively. Although the overall incidence of community-onset MSSA BSI (15.0 per 100 000) was rela-
tively similar across regions, the incidence rates of hospital-onset MSSA (9.2 per 100 000), community-onset MRSA (1.0 per 100 000)
and hospital-onset MRSA (0.8 per 100 000) BSI varied substantially. Whereas the overall incidence of S. aureus BSI did not increase over
the study period, there was an increase in the incidence of MRSA BSI. Major changes in the occurrence of community-onset and hospi-
tal-onset MSSA and MRSA BSI occurred, but these varied signiﬁcantly among regions, even within the same country. Although major
changes in the epidemiology of community-onset and hospital-onset MSSA and MRSA BSIs are occurring, this multinational population-
based study did not ﬁnd that the overall incidence of S. aureus BSI is increasing.
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Background
Staphylococcus aureus is the second most common cause of
bloodstream infection (BSI), and is the most important cause
of BSI-associated death [1–3]. Population-based studies con-
ducted in many regions around the world have identiﬁed
incidence rates of 15–40 per 100 000 population per year,
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with case-fatality rates of approximately 15–25% [4–16]. The
epidemiology of S. aureus BSI appears to be changing. Many
regions worldwide have witnessed increases in the overall
incidence of S. aureus BSI, and there have been increases in
the number and severity of BSIs caused by methicillin-resis-
tant S. aureus (MRSA), associated with the emergence of
community-associated strains in many areas [11,14,15,17–
25]. However, it is unclear whether these increases in MRSA
BSI may be replacing or adding to the burden of disease
caused by methicillin-sensitive S. aureus (MSSA) [6,13,22–
24,26–28]. In addition, it is not known to what extent
changes in the occurrence of both MSSA and MRSA BSI may
be attributable to shifts in incidence between community-
based and hospital-based patients.
In order to best establish the distribution and determinants
of an infectious disease, population-based studies are optimal.
This is because, in these designs, selection bias is minimized
by inclusion of all cases of disease occurring among residents
of a deﬁned population. Furthermore, by virtue of the fact
that all cases are identiﬁed among a known population, shifts
between subpopulations such as community and hospital can
be evaluated, and comparisons among different populations
and time periods are facilitated. With the exception of one
study that speciﬁcally compared MRSA incidence rates
between the UK and the USA [29], population-based studies
investigating the epidemiology of invasive or bacteraemic
S. aureus disease to date have been limited to single regions
or one country. The objective of this study was therefore to
deﬁne the occurrence of all MSSA and MRSA BSIs within a
large multinational population and to evaluate temporal and
regional differences. We were speciﬁcally interested in deter-
mining whether the overall incidence of S. aureus BSI has
been changing, and whether MRSA may be replacing or add-
ing to the burden of disease caused by MSSA.
Methods
Study protocol
This study utilized a multicentre population-based cohort
design. Active surveillance was conducted nationally in Fin-
land and in eight other regions within Australia, Canada,
Denmark and Sweden under the auspices of the International
Bacteremia Surveillance Collaborative [30]. All incident epi-
sodes of S. aureus BSI as deﬁned by the growth of this organ-
ism from one or more blood cultures from residents of the
surveillance populations during 1 January 2000 to 31 Decem-
ber 2008 were identiﬁed. Study laboratories were estimated
to identify 99% of all positive blood cultures from residents
of the surveillance regions, and were equipped with elec-
tronic information systems to allow complete retrieval of
recorded data. Patient age and gender were recorded, and
isolates were determined to be MSSA or MRSA with stan-
dard methodology, according to the protocols established in
each of the participating centres. Cases were classiﬁed as
hospital-onset if the ﬁrst culture was obtained more than
2 days after admission to hospital or within 2 days of dis-
charge, and as community-onset otherwise. The Conjoint
Health Research Ethics Board at the University of Calgary
approved this study, and each centre complied with their
local speciﬁc scientiﬁc and ethical review requirements.
Surveillance populations
The Canberra Region (population 370 000) includes the city of
Canberra within the Australian Capital Territory and the satel-
lite city of Queanbeyan and several small surrounding rural
towns within the state of New South Wales [31]. The three
Canadian centres included Sherbrooke (Quebec), Victoria
(British Columbia), and Calgary (Alberta). Sherbrooke has a
population of 152 000 residents, and is served by a single
microbiology laboratory located in the Centre Hospitalier Uni-
versitaire de Sherbrooke [13]. Data from the Victoria area
included the south local health area of the Vancouver Island
Health Authority (population 364 000), and cases were identi-
ﬁed at the regional microbiology laboratory [30]. Laboratory-
based surveillance in the Calgary Health Region (population
1.2 million) was conducted at Calgary Laboratory Services [32].
The Danish surveillance regions included the North Denmark
Region and two areas within the Capital Region of Denmark.
The North Denmark Region surveillance was conducted using
the previous boundaries of the North Jutland County (popula-
tion 495 000). Surveillance from the Capital Region of Den-
mark was conducted within the boundaries of the two prior
regions of Copenhagen City (population 640 000) and Copen-
hagen County (population 620 000). Surveillance data from Fin-
land (population 5.3 million) was obtained from the National
Infectious Disease Register, to which all Finnish clinical microbi-
ology laboratories report all bacterial isolations from blood
[33]. The Swedish surveillance region included the Skaraborg
County Health Region located in western Sweden (population
256 000), where cases occurring in the community and among
patients admitted to all four hospitals were identiﬁed [8].
Data management and statistical analysis
Data were analysed with Stata 11.2 (StataCorp, College Sta-
tion, TX, USA). For purposes of analysis, MSSA and MRSA
were considered independently. Only the ﬁrst isolate per
type per patient per year was included in analysis. The
incidence of S. aureus BSI was calculated by dividing the num-
ber of incident cases by the surveillance population as deter-
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mined by census data from each of the surveillance areas.
Incidence rates were reported after age (<1 year, and deciles
thereafter) and gender standardization to the 2007 27-coun-
try EU (EU27) population (http://epp.eurostat.ec.europa.eu).
Variability in incidence rates was assessed with the chi-square
test and the Cuzick non-parametric test for trend across
ordered groups. Although exact overall age-speciﬁc and gen-
der-speciﬁc incidence rates for MSSA and MRSA BSI were
available for all years, data deﬁning community-onset and hos-
pital-onset BSI were not available for 2002–2003 in Finland,
and these were estimated from adjacent years. The gender-
speciﬁc risk for the development of an S. aureus BSI and the
incidence rates between the two time periods 2000–2004
and 2005–2008 was determined by calculating an incidence
rate ratio (RR) with a 95% conﬁdence interval (CI).
Results
During the 9-year study involving more than 83 million
patient-years of observation, a total of 18 430 incident cases
of S. aureus BSI were identiﬁed, of which 17 618 (95.6%) were
MSSA and 812 (4.4%) were MRSA. The incidence was highest
in the very young and the elderly, as shown in Fig. 1. As com-
pared with females, males were at increased risk for any S. aur-
eus BSI (27.6 vs. 16.9 per 100 000; RR 1.63; 95% CI 1.59–1.68;
p <0.0001), and this was true for both MSSA BSIs (26.4 vs.
16.2 per 100 000; RR 1.63; 95% CI 1.58–1.68; p <0.0001) and
MRSA BSIs (1.2 vs. 0.7 per 100 000; RR 1.72; 95% CI 1.49–
1.99; p <0.0001).
The overall standardized annual incidence rate for S. aur-
eus BSI was 26.1 per 100 000 population, and those for
MSSA and MRSA BSIs were 24.2 and 1.9 per 100 000,
respectively. The overall adjusted incidence rates for S. aur-
eus BSI were markedly different (p <0.001) among the sur-
veillance regions, as shown in Fig. 2. Whereas the overall
incidence of community-onset MSSA BSI (15.0; range 11.9–
16.5 per 100 000) was relatively similar across regions, rates
of hospital-onset MSSA (9.2; range 3.1–17.0 per 100 000),
community-onset MRSA (1.0; range 0.04–2.4 per 100 000)
and hospital-onset MRSA (0.8; range 0–2.7 per 100 000) BSIs
varied substantially by surveillance area, as shown in Fig. 2.
Although there was evidence for year-to-year variability
(p <0.001) during the study period, there was no evidence to
support an overall annual change in incidence (p 0.8), as shown
in Fig. 3. However, the annual incidence of community-onset
S. aureus BSI increased signiﬁcantly (p <0.001). Although there
was no evidence to support an overall trend for an annual
increase in the incidence of MSSA BSI (p 0.8) or of hospital-
onset MSSA BSI (p 0.12), a signiﬁcant (p 0.005) increase in the
incidence of community-onset MSSA BSI was observed
(Fig. 3). The overall yearly incidence of MRSA BSI increased
(p 0.035), particularly in the second half of the study, and this
was principally attributable to increases in the numbers of
community-onset MRSA BSIs (p 0.013), as shown in Fig. 3.
The incidence of S. aureus BSI showed considerable vari-
ability by region (Fig. 4) and over time, even within coun-
tries, as shown in Table 1 and Appendix 2. In western
Sweden, there was a signiﬁcant increase in the incidence of
MSSA BSI that was related to an increase in the incidence of
community-onset BSI; MRSA BSI was rare. In Finland, an
increase in the incidence of BSI overall was observed, with
increasing numbers of cases of hospital-onset MSSA BSI and
both community-onset and hospital-onset MRSA BSI. In both
Canberra and Sherbrooke, the incidence rates of MSSA and
MRSA BSIs increased initially and then decreased, such that
an overall change was not observed. In Calgary, overall
FIG. 1. Age-speciﬁc and gender-speciﬁc incidence rates of Staphylo-
coccus aureus bloodstream infection, 2000–2008. MRSA, methicillin-
resistant S. aureus; MSSA, methicillin-sensitive S. aureus.
FIG. 2. Age-adjusted and gender-adjusted annual incidence rates of
Staphylococcus aureus bloodstream infection by region, 2000–2008.
H-MRSA, hospital-onset methicillin-resistant S. aureus; C-MRSA,
community-onset methicillin-resistant S. aureus; H-MSSA, hospital-
onset methicillin-sensitive S. aureus; C-MSSA, community-onset
methicillin-sensitive S. aureus.
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decreases in the incidence rates of both community-onset
and hospital-onset MSSA BSIs were observed, although there
were increased incidence rates of MRSA BSI. Although a sim-
ilar emergence of community-onset MRSA BSI occurred in
Victoria, unlike in Calgary this added to the incidence of
MSSA BSI, resulting in an overall increase in the burden of
disease. Both the North Denmark and Copenhagen City
regions witnessed an overall decrease in the incidence rates
of BSI, which was attributable to signiﬁcant decreases in the
incidence rates of hospital-onset MSSA BSI. In contrast, in
Copenhagen County, a decreasing incidence of hospital-onset
MSSA BSI was countered by an increase in the incidence of
community-onset MSSA BSI and a low but signiﬁcant additive
incidence of MRSA BSI, particularly in the community.
Discussion
This study has a number of important and novel attributes.
First, it is the largest (nearly 20 000 patients) study of S. aur-
eus BSI reported to date. Second, it includes all incident
cases of MRSA and MSSA BSI occurring in both the commu-
nity and hospital. As a result, we were able to evaluate over-
all effects in the population at large and detect shifts within
subgroups. Third, we included nine regions from ﬁve
countries in three continents. Following standardization
against a reference population, we were able to conduct
regional and international incidence rate comparisons.
Fourth, the study duration was 9 years, so year-to-year vari-
ability and trends over time could be observed over a long
period. Ultimately, this study provides new information on
the incidence of all S. aureus BSIs occurring in multiple popu-
lations around the globe, and highlights major regional differ-
ences in the epidemiology of S. aureus BSI.
There are only a few contemporary population-based
studies that have investigated the incidence of all S. aureus
BSIs in other populations around the globe for comparison.
Asgeirsson et al. [14] investigated S. aureus BSI among 692
adults in Iceland during 1995–2008, and found decreasing
nosocomial infection rates that were countered by increasing
rates in the community, giving an overall increasing incidence
of 22.7–28.9 per 100 000. El Atrouni et al. [15] studied
S. aureus BSIs among 247 adult residents of Olmsted County
TABLE 1. Changes in the occurrence of Staphylococcus aureus bloodstream infection
Centre C-MSSA H-MSSA MSSA C-MRSA H-MRSA MRSA All SA
North
Denmark
16.4 vs. 16.0; 1.02
(0.88–1.18)
11.6 vs. 16.5; 0.70
(0.60–0.83)
28.0 vs. 32.6; 0.86
(0.77–0.96)
0.05 vs. 0.04; 1.23
(0.02–96.91)
Two cases during
2005–2008
0.15 vs. 0.04; 3.70
(0.30–194.4)
28.1 vs. 32.6; 0.86
(0.77–0.96)
Calgary 14.0 vs. 16.4; 0.85
(0.77–0.94)
7.1 vs. 10.1; 0.71
(0.62–0.81)
21.1 vs. 26.5; 0.80
(0.74–0.86)
4.3 vs. 0.9; 4.93
(3.59–6.90)
3.1 vs. 1.2; 2.57
(1.91–3.48)
7.4 vs. 2.1; 3.57
(2.89–4.45)
28.6 vs. 28.6; 1.00
(0.93–1.08)
Copenhagen
City
15.9 vs. 17.0; 0.94
(0.82–1.07)
11.5 vs. 16.1; 0.71
(0.61–0.82)
27.4 vs. 33.1; 0.83
(0.75–0.91)
0.2 vs. 0.3; 0.72
(0.19–2.50)
0.01 vs. 0.02; 0.38
(0.07–1.54)
0.3 vs. 0.5; 0.58
(0.21–1.43)
27.7 vs. 33.7; 0.82
(0.75–0.91)
Copenhagen
County
16.6 vs. 13.2; 1.25
(1.09–1.44)
14.6 vs. 19.1; 0.76
(0.67–0.87)
31.1 vs. 32.3; 0.96
(0.88–1.06)
0.3 vs. 0.06; 5.01
(1.00–48.44)
0.3 vs. 0.1; 3.34
(0.80–19.55)
0.7 vs. 0.2; 4.00
(1.40–13.99)
31.8 vs. 32.5; 0.98
(0.89–1.08)
Canberra 14.4 vs. 14.6; 0.99
(0.82–1.19)
6.5 vs. 7.6; 0.86
(0.65–1.12)
20.9 vs. 22.1; 0.94
(0.81–1.10)
2.0 vs. 2.0; 0.98
(0.58–1.65)
2.9 vs. 2.6; 1.13
(0.73–1.76)
4.9 vs. 4.6; 1.07
(0.76–1.48)
25.7 vs. 26.7; 0.96
(0.84–1.11)
Finland 11.9 vs. 11.9; 1.00
(0.95–1.05)
9.0 vs. 6.5; 1.38
(1.29–1.48)
21.2 vs. 18.9; 1.13
(1.08–1.17)
0.2 vs. 0.09; 2.67
(1.61–4.52)
0.3 vs. 0.1; 2.95
(1.94–4.57)
0.6 vs. 0.2; 2.83
(2.06–3.93)
21.8 vs. 19.0; 1.15
(1.10–1.19)
Western
Sweden
21.6 vs. 15.3; 1.41
(1.16–1.72)
4.4 vs. 5.2; 0.85
(0.57–1.26)
26.1 vs. 20.5; 1.27
(1.07–1.52)
One case during
2005–2008
No cases No cases during
2000–2004
26.2 vs. 20.5; 1.28
(1.07–1.52)
Victoria 20.6 vs. 18.7; 1.10
(0.87–1.39)
2.5 vs. 3.5; 0.71
(0.46–1.09)
18.5 vs. 17.9; 1.03
(0.87–1.22)
5.4 vs. 1.8; 3.00
(1.61–5.88)
0.9 vs. 0.3; 2.57
(0.91–8.2)
4.7 vs. 1.6; 2.99
(1.89–4.85)
23.2 vs. 19.5; 1.19;
(1.02–1.39)
Sherbrooke 14.4 vs. 11.1; 1.30
(0.95–1.78)
5.6 vs. 5.7; 0.99
(0.61–1.60)
20.4 vs. 16.8; 1.19
(0.92–1.55)
1.8 vs. 1.7; 1.09
(0.44–2.71)
1.2 vs. 1.9; 0.60
(0.20–1.58)
3.0 vs. 3.6; 0.83
(0.43–1.56)
23.0 vs. 20.4; 1.13
(0.89–1.43)
Total 15.7 vs. 14.5; 1.09
(1.05–1.13)
8.1 vs. 10.0; 0.81
(0.77–0.84)
23.8 vs. 24.5; 0.97
(0.94–1.00)
1.4 vs. 0.7; 2.09
(1.82–2.41)
1.0 vs. 0.7; 1.35
(1.17–1.58)
2.4 vs. 1.4; 1.71
(1.55–1.90)
26.3 vs. 26.0; 1.01
(0.99–1.04)
C-MRSA, community-onset methicillin-resistant S. aureus; C-MSSA, community-onset methicillin-sensitive S. aureus; H-MRSA, hospital-onset methicillin-resistant S. aureus; H-
MSSA, hospital-onset methicillin-sensitive S. aureus; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-sensitive S. aureus; SA, S. aureus. Data are shown as age-adjusted
and gender-adjusted annualized incidence per 100 000 population during 2005–2008 vs. 2000–2004, incidence rate ratio, and 95% conﬁdence interval.
FIG. 3. Age-adjusted and gender-adjusted annual incidence rates for
Staphylococcus aureus bloodstream infection, 2000–2008. H-MRSA,
hospital-onset methicillin-resistant S. aureus; C-MRSA, community-
onset methicillin-resistant S. aureus; H-MSSA, hospital-onset methicil-
lin-sensitive S. aureus; C-MSSA, community-onset methicillin-sensitive
S. aureus.
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(USA) during 1998–2005, and found an overall annual inci-
dence of 38.2 per 100 000. Huggan et al. [16] identiﬁed 779
patients with S. aureus BSI in Christchurch (New Zealand)
during 1998–2005, and found an overall incidence of 21.6
per 100 000. Tong et al. [7], in Darwin (northern Australia),
reported on a 1-year study of 110 cases of S. aureus BSI, and
found an overall incidence of 65 per 100 000. However, this
high incidence was attributable to a dramatically increased
risk in the Aboriginal population (172 per 100 000), with the
incidence observed in the non-Aboriginal population (30 per
100 000) being similar to that observed in our surveillance
regions. Although these studies provide important informa-
tion, it must be recognized that, because some only included
adults [14,15], and age and gender proﬁles of populations
and study time frames were different, caution must be exer-
cised in attempts to directly compare results.
It is important to establish the incidence of infectious disease,
in order to deﬁne the burden of disease for the setting of
healthcare service, preventive and research priorities. There
are a number of factors that may inﬂuence the incidence of
S. aureus BSI in populations, and these are not limited to differ-
ences in demographics, healthcare systems and practice variabil-
ity among clinicians and laboratorians. We (Fig. 1), like others
[14–16], have observed that older age and male gender signiﬁ-
cantly increase the risk for S. aureus BSI. Populations that are
older or that have higher proportions of males may therefore
be expected to have higher crude incidence rates. Similarly, co-
morbid medical conditions, ethnicity and socio-economic status
inﬂuence the risk of disease, and their distribution in a popula-
tion will inﬂuence the incidence of S. aureus BSI [6,7,16]. In our
present study, we employed age and gender standardization to
a common population structure in order to minimize the inﬂu-
ence of demographic differences. In addition, all of our centres
are in high-income countries with extensive or completely pub-
licly funded healthcare and laboratory systems, such that there
are no ﬁnancial barriers to high-quality blood culture testing.
Therefore, the observed differences among our surveillance
regions probably reﬂect non-demographic population differ-
ences, variations in practice, and possibly different approaches
to infection prevention and control.
Although MSSA incidence, and in particular community-onset
BSI, was relatively similar among the study sites, the epidemiol-
ogy of MRSA BSI was vastly different. Incidence rates in the
Scandinavian centres were low, as expected, although these
were rising signiﬁcantly in Finland and in Copenhagen County.
Recent years have seen rising incidence rates of MRSA BSI in
many regions around the globe, especially with the emergence
of community-onset BSI [20]. The issue of whether the emer-
gence of MRSA has added to or replaced the burden of MSSA
BSI has been a topic of controversy. Mostofsky et al. [25]
recently reported a review of published studies on S. aureus
BSIs, and concluded that the emergence of MRSA has greatly
added to the burden of MSSA disease. However, it must be rec-
ognized that most of the studies that they included were per-
formed in selected patients, wards, or hospitals, such that shifts
into the community or the population at large could not be
detected. In our study, which included all cases occurring in the
entire population, we observed evidence for replacement in
Calgary 28.6
Victoria 21.1   Sherbrooke 21.5
Finland 20.3North Denmark 30.6
Copenhagen City 31.0
Copenhagen County 32.1
Canberra 26.3
Western Sweden23.0
FIG. 4. Annualized age-adjusted and gender-adjusted incidence rates (per 100 000 population) of Staphylococcus aureus bacteraemia in nine
surveillance populations during 2000–2008.
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some centres and additive effects in others. Most of the differ-
ences in the overall incidence of S. aureus BSI in our study were
related to changes in disease caused by MSSA.
Although we utilized a population-based design, there are
some limitations that merit discussion. First, we did not fur-
ther categorize our community-onset cases into community-
acquired or healthcare-associated BSI [34]. Second, we did
not utilize a central laboratory for species conﬁrmation [30].
Third, we did not include comorbidity, strain typing and
treatment data, which would have been helpful to explain
observed differences in incidence over time and among
regions. Finally, our study regions were all in high-income
industrialized countries with extensive publicly funded health
systems, and this may limit generalization to other regions.
In summary, this major study deﬁnes the contemporary
occurrence of S. aureus BSI in nine regions around the globe.
Although major changes in the epidemiology of community-
onset and hospital-onset MSSA and MRSA BSIs are occurring,
there is no evidence to suggest that the overall incidence of
S. aureus BSI is increasing. Given that there are signiﬁcant
regional differences in the population incidence of S. aureus
BSI, care should be exercised in generalizing results about the
epidemiology of S. aureus BSIs on the basis of previous studies
conducted in selected populations or single regions.
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The International Bacteremia Surveillance Collaborative
includes K. J. Kennedy, P. Collignon (Canberra, Australia),
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